Understanding Financial Toxicity in Myelofibrosis

EP: 1.Myelofibrosis Overview: US Incidence, Prognosis, and Patient Presentation

EP: 2.Unmet Needs in Myelofibrosis: Key Challenges in Disease Management

EP: 3.Impact of Myelofibrosis on Quality of Life: Key Clinical Features

EP: 4.Primary Management Goals and Importance of Risk Stratification in Myelofibrosis

EP: 5.JAK Inhibitors and Myelofibrosis Management: A Review of Current Treatments

EP: 6.Key Patient Factors Guiding Myelofibrosis Treatment Selection

EP: 7.Key Outcomes for Monitoring Myelofibrosis Treatment Response

EP: 8.Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis

Now Viewing

EP: 9.Understanding Financial Toxicity in Myelofibrosis

EP: 10.Advancing Myelofibrosis Treatment: What Lies Ahead

EP: 11.K-Cast Written Summary. Optimizing the Management of Myelofibrosis

Video content above is prompted by the following:

• From a patient perspective, what are some financial toxicity considerations that should be considered, particularly for those patients with co-insurance or high deductible health plan pharmacy benefit design?
  • For patients enrolled in high deductible health plans, how do lower WAC products affect their out-of-pocket expenses?